Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 11/20 | 1.00 |
| ▸ | MYC | P01106 | 1/20 | 0.77 |
| ▸ | MAX | P61244 | 1/20 | 0.77 |
| ▸ | PIM2 | Q9P1W9 | 10/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.67 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.64 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | GSK3B | P49841 | 2/20 | 0.62 |
| ▸ | MAOA | P21397 | 2/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | MAOB | P27338 | 1/20 | 0.62 |
| ▸ | IGF1R | P08069 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2543142 | 1.00 | PIM1 (1.00) | PIM1MYCMAXPIM2HPGD | |
| SCHEMBL2543140 | 1.00 | PIM1 (1.00) | PIM1MYCMAXPIM2HPGD | |
| SCHEMBL20816056 | 0.87 | MYC (1.00) | PIM1MYCMAXRAB9AMAOA | |
| SCHEMBL8179067 | 0.87 | MYC (1.00) | PIM1MYCMAXRAB9AMAOA | |
| SCHEMBL8179068 | 0.87 | MYC (1.00) | PIM1MYCMAXRAB9AMAOA | |
| SCHEMBL9375625 | 0.87 | PIM1 (0.77) | PIM1MYCMAXPIM2HPGD | |
| SCHEMBL9375624 | 0.87 | PIM1 (0.77) | PIM1MYCMAXPIM2HPGD | |
| SCHEMBL8187521 | 0.83 | PIM1 (0.70) | PIM1MYCMAXPIM2HPGD | |
| SCHEMBL23036923 | 0.82 | MTOR (0.80) | PIM1MYCMAXPIM2HPGD | |
| SCHEMBL8001434 | 0.80 | AKR1B1 (0.71) | PIM1PIM2HPGDPIM3AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133186-B2 | Hetero ring-fused imidazole derivative having AMPK activating effect | SHIONOGI & CO., LTD. (JP) | 2015-09-15 | — | — | US | disclosed |
| US-20130184240-A1 | HETERO RING-FUSED IMIDAZOLE DERIVATIVE HAVING AMPK ACTIVATING EFFECT | SHIONOGI & CO., LTD. (JP) | 2013-07-18 | — | — | US | disclosed |
| US-20110263664-A1 | Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263664-A1 | Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263664-A1 | Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2011-10-27 | — | — | US | disclosed |
| WO-2009064486-A9 | INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS, AND METHODS FOR TREATING CANCER | MUSC FOUND FOR RES DEV (US) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184240-A1 | HETERO RING-FUSED IMIDAZOLE DERIVATIVE HAVING AMPK ACTIVATING EFFECT | PRKAA1, PRKAA2, PRKAG1 | PIM1 1972/4885MYC 1063/4885MAX 923/4885 |
| US-20110263664-A1 | Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer | PIM1, PIM2, PIM3 | PIM1 1/4885MYC 4/4885MAX 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.